文 | 酒讯 半颗 编辑 | 方圆 酒讯了解到，这场"大师宴"仅邀请了10余位企业家、金融从业者入席，共同品鉴内参大师酒十五年。自5月以来，该活动已在全国举办29场，在湖南一省 就覆盖长沙、株洲、湘潭、衡阳、岳阳、常德、怀化、娄底等多个城市。每场宴席通常维持在12至15人，参与者多为当地商界人士、金融从业者或文化圈 意见领袖，形态更接近高净值人群的私密聚会。 整体来看，"内参大师宴"强调"小而美、精而深"，以"仅邀约真正懂酒、懂文化的大师级嘉宾"的方式，让活动的重心更偏向深度交流。 内参·大师宴 图片来源：酒鬼酒公众号 内参酒销售公司大师酒业务推广部总监朱旭强调，"真正的高端消费靠'人'与'圈'的影响。"对酒鬼酒来说，这意味着从以往的大范围触达，转向把资源集 中投向更明确、消费力更强的核心人群，完成了一次圈层"瘦身"。 日前，湖南怀化的一张长桌上，十余位企业家围坐，品尝酒鬼酒产品"内参·大师酒十五年"。这场名为"内参·大师宴"的小范围圈层营销活动，可谓是酒鬼 酒近两年的战略转向的缩影——过去依靠大经销商体系与高端化攻势挥师全国的酒鬼酒，正在进行一次"瘦身"实践，将战略从做大转向做精。 回顾过去酒鬼酒的战略调整 ...

Core Viewpoint - The company, Darentang, reported a significant increase in net profit by 193% to 1.928 billion yuan, while revenue plummeted by 33.15% to 2.651 billion yuan, marking the third consecutive year of revenue decline [1] Financial Performance - Net profit surged to 1.928 billion yuan, primarily supported by the sale of key assets [1] - Revenue fell to 2.651 billion yuan, continuing a downward trend with projected declines of 0.33% and 11.14% for 2023 and 2024 respectively [1] - The sale of a 12% stake in Tianjin Schering Pharmaceutical generated a post-tax net gain of 1.308 billion yuan, significantly boosting net profit [1] - Excluding this asset sale, the adjusted net profit was only 596 million yuan, reflecting a year-on-year decline of 5.99% [1] Asset Management - The divestment of Tianjin Schering, a key profit contributor, raises concerns about the company's long-term cash flow stability [1] - The company has exited a partnership that previously provided nearly 25% of its investment income in 2023 [1] - Both asset sales were executed at a 35% premium, but market sentiment remains cautious regarding future cash flow [1] Product Performance - Traditional Chinese medicine accounts for 91.47% of the company's revenue, with "Suoxiao Jiuxin Wan" showing only a slight sales increase of 5.45% to 1.128 billion yuan [1] - The promising "Qingyan Diban" product saw a substantial increase of 52.28% to 289 million yuan, but its small scale limits its impact [1] Compliance and Quality Issues - The company has faced multiple quality compliance issues, including penalties for substandard products and GMP deficiencies reported by the FDA [2] - Complaints related to quality, marketing, and after-sales service have exceeded 20 since 2025 [2] - The company's "slimming strategy" has led to short-term financial gains but has also resulted in weakened revenue-generating capabilities and cash flow [2] Strategic Challenges - The company is experiencing a lack of new product development to replace declining sales from its flagship products [2] - The lengthy innovation cycle in traditional Chinese medicine poses challenges for immediate revenue recovery [2] - The need for a return to product innovation and compliance is emphasized as essential for sustainable growth [2]